Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canagliflozin in pediatric type 2 diabetes
CTR20181597Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of canagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Janssen Pharmaceutical. Started Sep 2018; status: completed.
02
Drugs
canagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20181597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181597.